3D Microtissues Help Big Pharma in New Drug Development

(startupticker.ch, July 12, 2013)

Big pharma companies Roche and Pfizer have presented results highlighting the advantages of the 3D microtissues of Swiss startup InSphero. At the annual meeting of the Society of Toxicology, Pfizer showed how InSphero's tissues deliver excellent results predicting liver toxicity. Roche was for the first time able to reproduce the working mechanism of a complex, antibody-based anti-tumor drug thanks to the organotypic microtissues by InSphero. "These are just two example of how our technology can aid pharma companies in the development of new substances", explains Dr. Jan Lichtenberg, CEO and Co-Founder of InSphero.